COVID-19 Rapid Antibody Test
(IgG/IgM to SARS-CoV-2 Spike Protein)
Recently received Emergency Use Authorization (EUA) from the US FDA.
Single drop whole blood needed to do the test.
No special expertise or instrument needed.
The test is 100% specific and 97.5% sensitive.
Can be performed at the point of care in an independent or hospital laboratory.
Takes 2-10 minutes to get the results.
Paid by all public and private insurances.
Very affordable for a private pay option.
Ideal for businesses ready to reopen
Great for hospitals employees and patients.
Only available way to gauge immunity against COVID.
By playing an active role in advancing innovation and helping collaborating organizations in transferring or adopting cutting-edge technologies, BioCentra is committed to leading an ecosystem that offers hope to patients, accelerates development of effective therapies, simplifies access to affordable care, encourages technological competence of its clients from developing nations with western partners, opens avenues of regional growth and increased global economic opportunity, while adhering to the highest standards of excellence in technology innovation, product development and strategic consulting with high standards of professional integrity and business ethics that is considerate of human, moral, religious, economic and community values.
BioCentra (incorporated in the State of Texas in 2008) started with a mission of advancing biomedical science and biotechnology through education, technology innovation, new product development, customized research services, strategic consulting and project management by collaborating with industry and academia, both nationally and internationally.
Driven by Success
We develop novel and sustainable products and technologies in bio-therapeutics, vaccines and personalized diagnostics of cancer and infectious diseases. Most of our efforts have been directed toward in-house innovation in drug development and diagnostics; biotechnology consulting to pharmaceutical companies interested in technologies related to biosimilar and biologics development; and specialized contract research services to clinical and academic research institutions in order to design solutions based on novel methods and protocols useful in clinical validation of biopharmaceutical molecules and vaccines.
DO YOU NEED EXPERTS IN DEVELOPING A NEW PRODUCT? WE ARE HERE TO HELP.
Molecular & Genomic
Resources & Core Competencies
Biopharmaceutical research and technology development infrastructure
Multiple product knowledge and technological know-how
Agreements with technology collaborators & alliance partners from US & Europe
International business development experience with access to distinctive global distribution network and knowledge of emerging products and technologies
Access to experienced manpower in science, technology, engineering and QC
Expertise in Efficient Process Development & Engineering Design
High-level subject matter, business proposals, and financial analysis expertise
Extensive Knowledge of International markets, regulations, compliances and policy
Expertise in Strategic Project Management with an Innovative Management TeamAccess to Experts in Industrial Design and Turnkey Manufacturing Resources.
Custom, R&D and Pre-Clinical Pipeline
Peptide-Drug conjugate for the treatment of prostate and lung cancer in pre-clinical phase.
Synthetic adjuvant for peptide vaccines in cancer and infectious diseases in clinical phase.
Viral Load Technology
Fast, efficient and cost-effective diagnostic technology for viral load assay development.
Bio-topical for DFU
Biopharmaceutical drug product for diabetic foot ulcers and wound healing in pre-clinical phase.